LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for the treatment of MF-CTCL in adult patients). Since June 2019, LEDAGA® is commercialized in more than 30 countries including Europe, Canada, Latin America.*
*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country.